Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Income from Discontinued Operations (2009 - 2018)

Charles River Laboratories International (CRL) posted Income from Discontinued Operations of $1.5 million for Q2 2018, up 6747.83% on a QoQ basis from -$23000.0 in Q1 2018, and up 2253.52% year-over-year from $64966.5 in Q2 2017.

Analysis

Charles River Laboratories International (CRL) Income from Discontinued Operations (2009 - 2018) Analysis & Trends

Charles River Laboratories International has reported Income from Discontinued Operations for 10 years, with the latest figure at $1.5 million in Q2 2018.

  • On a quarterly basis, Income from Discontinued Operations rose 2253.52% year-over-year to $1.5 million in Q2 2018; TTM through Mar 2019 was $1.5 million, a 1080.13% increase from a year earlier, with the FY2018 full-year figure at $1.5 million, up 1199.27% from the prior year.
  • Income from Discontinued Operations was $1.5 million for Q2 2018 at Charles River Laboratories International, up from -$23000.0 in the prior quarter.
  • The five-year high for Income from Discontinued Operations was $1.5 million in Q2 2018, with the low at -$902000.0 in Q4 2015.
  • Average Income from Discontinued Operations over 5 years is -$57055.6, with a median of -$24500.0 recorded in 2016.
  • The sharpest annual moves came in 2014 and 2018: Income from Discontinued Operations slumped 953.66% in 2014, then soared 2253.52% in 2018.
  • Over 5 years, Income from Discontinued Operations stood at -$864000.0 in 2014, then slipped by 4.4% to -$902000.0 in 2015, then soared by 94.68% to -$48000.0 in 2016, then soared by 52.08% to -$23000.0 in 2017, then soared by 6747.83% to $1.5 million in 2018.
  • The last three Income from Discontinued Operations figures came in at $1.5 million (Q2 2018), -$23000.0 (Q1 2018), and -$23000.0 (Q4 2017), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn -
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn -
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn 10.61 Mn
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn -
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 1.53 Mn
Mar 31, 2018 -23,000.00
Dec 30, 2017 -23,000.00
Sep 30, 2017 -39,000.00
Jul 1, 2017 -71,000.00
Apr 1, 2017 -4,000.00
Dec 31, 2016 -48,000.00
Sep 24, 2016 342,000.00
Jun 25, 2016 12,000.00
Mar 26, 2016 -26,000.00
Dec 26, 2015 -902,000.00
Sep 26, 2015 -34,000.00
Jun 27, 2015 -7,000.00
Mar 28, 2015 -7,000.00
Dec 27, 2014 -864,000.00
Sep 27, 2014 52,000.00
Jun 28, 2014 -644,000.00
Mar 29, 2014 -270,000.00
Dec 28, 2013 -82,000.00
Sep 28, 2013 -113,000.00